Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21 million in Q2 2025, reflecting a 43% year-over-year growth, and expects to achieve operating break-even for the full year [3][4][5] - The company has a strong recurring revenue stream, with $9.2 million in Q2, representing a 53% year-over-year increase, and over 40% of total revenue coming from recurring sources [4][5][9] - Sofwave's innovative technology and FDA clearances are driving rapid adoption in the aesthetic medical device market, with over 600,000 treatments conducted since launch [3][8][9] Financial Highlights - Q2 2025 revenue reached $21 million, a 43% increase from $14.6 million in Q2 2024; gross profit was $15.9 million, up 42% year-over-year [4][5][7] - First half revenue totaled $37.7 million, a 35% increase year-over-year, with gross profit of $28.6 million, reflecting a 36% growth [5][7] - The company generated $3.6 million in cash during Q2 2025, with cash and cash equivalents amounting to $24 million as of June 30, 2025 [4][5] Operational Highlights - Sofwave's technology, SUPERB™, is FDA-cleared for various aesthetic treatments, including wrinkle reduction and muscle toning, enhancing its market position [8][9] - The company has seen significant growth in brand awareness, surpassing 1 million social media followers, which supports its market presence [3][4] - Sofwave's operational discipline and strong balance sheet are key factors in its ongoing growth strategy [3][9]

Core Insights - Sofwave Medical Ltd reported a first quarter revenue of $16.7 million, reflecting a 26% year-over-year growth, with a gross margin of 76.3% [1][8] - The company achieved a recurring revenue of $7 million, marking a 49% year-over-year increase, which now constitutes over 40% of total revenue [1][5] - Sofwave's operating loss was reported at $1 million under IFRS and $0.2 million under non-IFRS, indicating stable performance compared to the previous year [1][8] Financial Highlights - First quarter revenue reached $16.7 million, a 26% increase from $13.2 million in Q1 2024 [10] - Gross profit for the quarter was $12.7 million, up 28% year-over-year [8][10] - The company maintained a gross margin of 76.3%, slightly up from 75.2% in the same quarter last year [10] - Cash and cash equivalents stood at $20.4 million as of March 31, 2025, with cash used in the quarter amounting to $1.2 million [8] Management Commentary - CEO Louis Scafuri highlighted strong revenue growth and market leadership, attributing success to new system placements and increased procedure volumes [3] - The company achieved regulatory clearance in Japan, opening new opportunities in the APAC region [4] - The launch of the LiftHD™ body applicator generated significant market enthusiasm, reinforcing Sofwave's position in non-invasive regenerative aesthetics [4][5] Operational Highlights - Over 520,000 treatments have been conducted since the initial market approval of Sofwave's technology [9] - The company is on track to achieve operating break-even in 2025 [9] - The widespread use of GLP-1 inhibitors is driving demand for Sofwave's skin lifting and muscle toning treatments [5]